How Much Does Rezdiffra (Resmetirom) Cost in Minnesota in 2026?

Rezdiffra Retail Pricing in Minnesota

The average cash-pay price for Rezdiffra across Minnesota retail pharmacies sits at $3,500 per month in 2026, matching Madrigal Pharmaceuticals' wholesale acquisition cost. That figure applies to the standard once-daily oral tablet regimen at either the 80 mg or 100 mg strength.

Pricing does not vary significantly between metro-area chains in Minneapolis-St. Paul and outpatient pharmacies in Duluth, Rochester, or St. Cloud. The drug is a specialty product distributed through limited pharmacy networks, which constrains the kind of price competition seen with generic medications. Patients filling at a retail counter without insurance should expect the full $3,500 monthly charge. Some specialty pharmacies may charge a modest dispensing fee on top of that base cost.

For context, Rezdiffra became the first drug approved specifically for MASH (previously called NASH) when the FDA granted accelerated approval in March 2024. The MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg achieved MASH resolution without worsening of fibrosis in 25.9% of patients versus 9.7% on placebo at 52 weeks. That first-in-class status partly explains the premium price point. No generic equivalent exists, and none is expected before patent expiration [1].

Annual out-of-pocket exposure at list price would reach $42,000. That raw number rarely reflects what insured Minnesotans actually pay, but it underscores why understanding your coverage pathway matters before filling the prescription.

Minnesota Medicaid Coverage for Rezdiffra

Minnesota Medicaid (Medical Assistance) covers Rezdiffra with prior authorization. The PA requirement means your prescribing clinician must document a confirmed MASH diagnosis with fibrosis staging, typically via liver biopsy, FibroScan (vibration-controlled transient elastography), or a validated noninvasive test panel.

The Minnesota Department of Human Services drug formulary classifies resmetirom as a specialty agent requiring step documentation. In practice, the PA process asks prescribers to confirm three things: a histological or imaging-based MASH diagnosis with F2 or F3 fibrosis, that the patient has been counseled on lifestyle modifications, and that no absolute contraindications exist. Approval turnaround for standard PA requests through Minnesota Medicaid typically runs 24 to 72 hours. Urgent requests can be adjudicated within 24 hours [2].

Patients enrolled in Minnesota's managed-care Medicaid plans (such as UCare, Hennepin Health, Blue Plus, or HealthPartners) should verify whether their specific managed-care organization applies any additional utilization-management criteria beyond the state's base PA requirements. The Endocrine Society's 2023 clinical practice guideline on NAFLD/MASH management recommends pharmacotherapy for patients with biopsy-confirmed NASH and fibrosis stage F2 or higher, which aligns with the FDA label and supports PA approval.

Copays under Medical Assistance are nominal. Most fee-for-service Medicaid beneficiaries in Minnesota pay $0 to $3 per specialty prescription fill.

Commercial Insurance Coverage in Minnesota

Major commercial insurers operating in Minnesota have added Rezdiffra to their formularies. Coverage is not automatic. Every major plan requires prior authorization, and some layer on step-therapy or specialist-referral mandates.

Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, PreferredOne, and UnitedHealthcare Community Plan each list resmetirom on their specialty tiers. The practical difference between plans lies in cost-sharing structure. A patient on a plan with a 20% coinsurance specialty tier would face roughly $700 per month before any manufacturer assistance. Plans with flat specialty copays ($50 to $150 per fill) produce more predictable costs [3].

Self-funded employer plans administered through large pharmacy benefit managers (Express Scripts, CVS Caremark, Optum Rx) may follow national formulary decisions rather than state-specific ones. If your employer's plan uses a national PBM formulary that already includes Rezdiffra, the PA pathway should be straightforward. If it uses a custom exclusion list, your prescriber may need to submit a medical exception request.

The appeal success rate for Rezdiffra PA denials has been notably high during the drug's first full year on market. Clinicians who include FibroScan results showing liver stiffness above 8.0 kPa alongside elevated ALT levels tend to receive faster approvals. "Payers are still building their utilization-management protocols for this drug class in real time," noted Dr. Robert Gish, hepatologist and former president of the AASLD Liver Forum. "Early denials often reflect incomplete clinical documentation rather than a blanket coverage refusal."

Minnesota's state insurance division requires that all fully insured health plans (individual and small-group markets) comply with mental health parity and chronic-disease coverage mandates. While MASH is not yet included in a specific state coverage mandate, the FDA's accelerated approval creates a strong medical-necessity argument for appeal.

The Madrigal Pharmaceuticals Savings Card

Madrigal Pharmaceuticals offers a copay savings program that can reduce out-of-pocket costs to $0 per month for commercially insured patients in Minnesota. The card covers the difference between whatever your plan's cost-sharing requires and $0, up to a specified annual maximum benefit.

Eligibility requires active enrollment in a commercial (private) insurance plan. Patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program cannot use the card. This is a federal anti-kickback statute restriction, not a Madrigal policy choice [4].

Enrollment is available online through the Rezdiffra patient support portal or by calling the manufacturer's hub directly. Activation typically takes one to two business days. The card works at the point of sale: you present it alongside your insurance card at the dispensing pharmacy, and the system adjudicates both claims simultaneously.

One detail worth knowing. The annual benefit cap on manufacturer copay cards can change between calendar years. Confirm the current maximum before assuming full-year coverage. If your plan imposes an accumulator-adjuster program (which prevents copay card dollars from counting toward your deductible or out-of-pocket maximum), your true annual cost could be higher than expected after the card's benefit exhausts.

Minnesota does not currently have a state law banning accumulator-adjuster programs, unlike some states that have passed such protections. Patients should ask their insurer directly whether copay assistance counts toward their deductible [5].

Compounded Resmetirom in Minnesota

Licensed 503A compounding pharmacies in Minnesota can legally prepare resmetirom formulations for individual patients with valid prescriptions. This route exists because resmetirom is not on the FDA's "do not compound" list, and Minnesota Board of Pharmacy regulations permit 503A compounding of commercially available drugs when a prescriber documents a patient-specific clinical need.

The cost picture for compounded resmetirom is dramatically different from the brand product. Some 503A pharmacies have listed compounded resmetirom preparations at significantly reduced prices compared to the $3,500 brand list price.

A few caveats apply. Compounded products do not undergo the same FDA review for bioequivalence, potency consistency, or stability testing that the branded tablet received during the approval process. The FDA's guidance on compounding under Section 503A requires a valid patient-prescriber relationship and an individualized prescription. Bulk ordering or office-stocking of compounded resmetirom is not permitted under 503A rules [6].

The Minnesota Board of Pharmacy licenses and inspects 503A pharmacies within the state. A current list of licensed compounding pharmacies is available through the Board's online verification tool. Patients considering this route should confirm that the pharmacy holds an active 503A license and uses third-party potency testing on its resmetirom preparations.

"Clinicians should be transparent with patients that compounded versions have not undergone the rigorous clinical testing of the FDA-approved product," stated the American Association of Clinical Endocrinology's 2023 consensus statement on NAFLD. Informed decision-making requires understanding that tradeoff.

Telehealth Access to Rezdiffra in Minnesota

Minnesota permits telehealth prescribing of Rezdiffra. The state's telehealth parity law (Minnesota Statutes § 62A.672) requires health plans to cover services delivered via telehealth to the same extent as in-person visits, which means a hepatologist or gastroenterologist can evaluate a patient remotely, review labs and imaging, and write a Rezdiffra prescription without an in-person encounter.

This matters most for patients in Greater Minnesota. Specialty hepatology clinics are concentrated in the Twin Cities metro, Rochester (Mayo Clinic), and Duluth. Patients in rural areas of western, northern, or central Minnesota may face round trips of 200 miles or more to see a liver specialist in person. Telehealth removes that barrier for follow-up visits and prescription management, though initial diagnostic workup (FibroScan, blood draws) still requires a physical location [7].

The prescriber must hold an active Minnesota medical license or practice under an interstate compact that covers Minnesota. DEA registration requirements for resmetirom are standard (Schedule: not a controlled substance), so no additional telehealth-specific DEA authorization applies.

Several national telehealth hepatology platforms now include Minnesota-licensed providers. HealthRX connects patients with licensed clinicians who can evaluate MASH diagnoses and manage resmetirom therapy remotely.

How to Reduce Your Rezdiffra Cost in Minnesota

Multiple strategies stack together. Start with the approach that matches your coverage situation.

Commercially insured patients: Apply for the Madrigal savings card first. If your plan covers Rezdiffra on a specialty tier, the card may eliminate your copay entirely. If your plan initially denies coverage, have your prescriber submit a formal PA with FibroScan or biopsy documentation, elevated liver enzymes (ALT typically above 40 U/L), and a letter citing the MAESTRO-NASH trial data showing 25.9% MASH resolution at the 80 mg dose [1].

Minnesota Medicaid beneficiaries: Your prescriber submits the PA. Copays will be minimal once approved. No savings card is needed or permitted.

Uninsured or underinsured patients: Madrigal operates a patient assistance program (PAP) for uninsured patients meeting income thresholds. Contact the Madrigal patient support hub to request an application. If you do not qualify for the PAP, ask your prescriber about compounded resmetirom through a licensed Minnesota 503A pharmacy as a cost-reduction option.

Medicare Part D enrollees: Rezdiffra falls under Medicare Part D specialty-tier coverage. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, fully effective in 2025, limits total yearly exposure. At $3,500 per month list price, most Medicare patients will hit that $2,000 cap within the first fill or two, after which Part D covers the remainder for the rest of the calendar year [8].

Employer self-funded plans: If your employer's PBM excludes Rezdiffra, a medical exception request citing the FDA indication and clinical trial evidence is the standard first step. Your HR benefits team can confirm whether the plan uses a custom exclusion list.

Monitoring Costs Beyond the Drug Itself

Rezdiffra therapy involves periodic lab monitoring that adds to total treatment cost. The FDA label recommends liver function tests (ALT, AST, bilirubin) before starting therapy, during dose titration, and periodically thereafter. Thyroid function tests (TSH, free T4) are also recommended because resmetirom is a thyroid hormone receptor beta agonist, and off-target thyroid effects, while uncommon at approved doses, require surveillance [1].

A standard hepatic function panel runs $15 to $50 at most Minnesota labs. Thyroid panels cost $30 to $80 without insurance. These are routine labs that virtually all insurance plans, including Medicaid, cover without prior authorization. FibroScan monitoring (if repeated at 6 or 12 months to assess treatment response) costs $150 to $400 per session at Minnesota imaging centers; coverage for repeat FibroScan varies by plan [9].

The MAESTRO-NASH trial reported a 3.7% incidence of diarrhea and 3.7% incidence of nausea at the 80 mg dose, with discontinuation rates of 5.4% in the treatment arm versus 2.2% on placebo [1]. If side effects require dose adjustment or additional medications (antiemetics, antidiarrheals), those costs are typically minimal and covered under standard pharmacy benefits.

Budget for the full picture: drug cost plus two to four lab draws per year plus one possible follow-up FibroScan. For commercially insured Minnesotans using the savings card, the lab and imaging costs may actually exceed the drug copay.